The objective of this study was to investigate the use of folate-targeted liposomes for the
delivery of encapsulated oligonucleotides to folate receptor (FR)-positive tumor cells in vitro and …

The pharmacokinetics of a 2′-O-(2-methoxyethyl)-ribose modified phosphorothioate
oligonucleotide, ISIS 104838 (human tumor necrosis factor-α antisense), have been characterized …

The objective of this study was to encapsulate an oligonucleotide drug within poly(lactide)
microparticles with high encapsulation efficiencies at high theoretical drug loadings by the …

… Anterior scintigraphic images, each 50 s duration were recorded using a gamma camera (General
Electric Maxicamera) fitted with a low energy parallel hole collimator. Images of 50 s …

The efficacy of low doses of flunixin meglumine in reducing eicosanoid generation and
clinical signs in response to experimentally induced endotoxaemia was investigated. …

… Teng, GE Hardee, and PE Daddona. Transdermal delivery of antisense oligonucleotides …
Johnson, CL Teng, GE Hardee, and PE Daddona. Transdermal delivery of antisense …

In vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838,
a phosphorothioate antisense oligonucleotide targetting human tumour necrosis factor …

Antisense oligodeoxynucleotides formulated in cream preparations are being examined in
the clinic as topical therapy for psoriasis. To produce their intended anti-inflammatory effects, …

Two cyclooxygenase inhibitors (flunixin meglumine and phenylbutazone) and a selective
thromboxane synthetase inhibitor were assessed in the management of experimental equine …

Antisense oligodeoxynucleotides (ODNs) possess great potential as sequence-specific
therapeutic agents. Sufficient concentrations of intact ODN must bypass membrane barriers and …